Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

We still don't know the true effectiveness of remdesivir. Photo: Ulrich Perrey/AFP via Getty Images

Depending on the study, remdesivir is either a clinical failure or a godsend for treating the novel coronavirus.

The big picture: The grim reality of the coronavirus pandemic has the world itching to know which experimental treatments actually work, but we're not necessarily getting any smarter from these incremental drips of incomplete information.

Driving the news: Remdesivir — an antiviral drug that some experts have seen as a promising coronavirus treatment — "was not associated with clinical or virological benefits" for coronavirus patients, according to a summary of a clinical trial in China, viewed by STAT and the Financial Times.

Between the lines: The truth is, we still don't really know how effective the drug is in fighting this virus.

  • The Chinese trial has a randomized control group, so it is by far the most reliable study. However, the trial has not gone through peer review, and Gilead said the results were "inconclusive" because the trial had to be terminated early.
  • The University of Chicago study and a Gilead-sponsored compassionate use study, which prompted rosier views of the drug, are riddled with flaws that make them hard to rely on. The most obvious drawback in both is the lack of a control group.

The bottom line: Science is slow for a reason, and the deluge of poorly designed trials and early drafts of studies is sowing confusion instead of creating clarity.

  • "The world is, unfortunately, getting a crash course in the value of evidence-based medicine vs. anecdote," veteran pharmaceutical analyst Brian Skorney tweeted.

What's next: A more rigorous report from Gilead's Chinese trial is expected at the end of this month, and data from other trials is expected in late May. Don't jump to any firm conclusions before that happens.

Go deeper: The high stakes of low scientific standards

Go deeper

Updated Oct 7, 2020 - Health

World coronavirus updates

Expand chart
Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Axios Visuals

New Zealand now has active no coronavirus cases in the community after the final six people linked to the Auckland cluster recovered, the country's Health Ministry confirmed in an email Wednesday.

The big picture: The country's second outbreak won't officially be declared closed until there have been "no new cases for two incubation periods," the ministry said. Auckland will join the rest of NZ in enjoying no domestic restrictions from late Wednesday, Prime Minister Jacinda Ardern said, declaring that NZ had "beat the virus again."

Updated 12 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Brendan Lynch/Axios

  1. Health: Coronavirus cases aren't budging — even after vaccinations doubled— Health care workers feel stress, burnout more than a year into the pandemic — Handful of "breakthrough" COVID cases occurred in nursing homes, CDC says.
  2. Vaccines: Johnson & Johnson's vaccine production problems look even bigger — All U.S. adults now eligible for COVID-19 vaccine.
  3. Political: Watchdog says agency infighting increased health and safety risks at start of pandemic.
  4. World: EU regulator: Benefits of J&J vaccine outweigh risk of rare blood clots.
  5. Variant tracker: Where different strains are spreading.

Trump says Fauci is "wrong" about coronavirus cases surge

President Trump and National Institute of Allergy and Infectious Diseases director Anthony Fauci during an April daily coronavirus task force briefing at the White House. Photo: Drew Angerer/Getty Images

President Trump called out Anthony Fauci Saturday in a comment retweeting a video of the NIAID director explaining why coronavirus cases have been surging in the U.S.

Driving the news: In the video of Friday's testimony, Fauci explained that while European countries shut 95% of their economies, the U.S. "functionally shut down only about 50%." Trump responded, "Wrong! We have more cases because we have tested far more than any other country, 60,000,000.